Safety and Tolerability of the Ophthalmic Solution PRO-179 Compared With Travatan®
Status:
Completed
Trial end date:
2019-08-29
Target enrollment:
Participant gender:
Summary
Phase I clinical study, to evaluate the safety and tolerability of the ophthalmic solution
PRO-179 compared with Travatan®, on the ocular surface of clinically healthy subjects.
Goals: To evaluate the safety and tolerability of the formulation PRO-179 manufactured by
Sophia Laboratories S.A. of C.V. on the ocular surface of clinically healthy subjects.
Hypothesis:The ophthalmic solution PRO-179 presents a profile of safety and tolerability
similar to Travatan® in healthy subjects.
Methodology: Clinical trial Phase I, controlled, of parallel groups, double blind, with
randomization.